CANTOS
2017
Canakinumab Anti-inflammatory Thrombosis Outcomes Study
In 10,061 patients with prior MI and elevated CRP, canakinumab reduced recurrent cardiovascular events compared with placebo.
Result
Efficacy: CV death, MI or strokeHR 0.85 (95% CI 0.74-0.98) · P = 0.021
Below 1 favours canakinumab, above 1 favours placebo.
Also reported: More fatal infections; no LDL change
- Subtopic
- Anti-inflammatory
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Ridker PM, et al. N Engl J Med. 2017;377(12):1119-1131.doi 10.1056/NEJMoa1707914
Discussion & critique
Proved the inflammatory hypothesis of atherosclerosis with a lipid-neutral drug. Cost and infection risk preclude routine use; pointed the way to colchicine.